CLBT vs. OKTA, MNDY, BSY, DOCS, MBLY, PAYC, RBRK, YMM, AUR, and PCOR
Should you be buying Cellebrite DI stock or one of its competitors? The main competitors of Cellebrite DI include Okta (OKTA), monday.com (MNDY), Bentley Systems (BSY), Doximity (DOCS), Mobileye Global (MBLY), Paycom Software (PAYC), Rubrik (RBRK), Full Truck Alliance (YMM), Aurora Innovation (AUR), and Procore Technologies (PCOR). These companies are all part of the "computer software" industry.
Cellebrite DI vs.
Okta (NASDAQ:OKTA) and Cellebrite DI (NASDAQ:CLBT) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking.
Okta received 526 more outperform votes than Cellebrite DI when rated by MarketBeat users. However, 66.15% of users gave Cellebrite DI an outperform vote while only 58.36% of users gave Okta an outperform vote.
Okta currently has a consensus price target of $105.67, suggesting a potential upside of 16.77%. Cellebrite DI has a consensus price target of $23.43, suggesting a potential upside of 26.23%. Given Cellebrite DI's stronger consensus rating and higher probable upside, analysts clearly believe Cellebrite DI is more favorable than Okta.
Cellebrite DI has lower revenue, but higher earnings than Okta. Okta is trading at a lower price-to-earnings ratio than Cellebrite DI, indicating that it is currently the more affordable of the two stocks.
Okta has a net margin of -1.54% compared to Cellebrite DI's net margin of -70.54%. Cellebrite DI's return on equity of 58.70% beat Okta's return on equity.
86.6% of Okta shares are owned by institutional investors. Comparatively, 45.9% of Cellebrite DI shares are owned by institutional investors. 7.0% of Okta shares are owned by insiders. Comparatively, 5.7% of Cellebrite DI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Okta has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Cellebrite DI has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
In the previous week, Okta had 17 more articles in the media than Cellebrite DI. MarketBeat recorded 27 mentions for Okta and 10 mentions for Cellebrite DI. Cellebrite DI's average media sentiment score of 0.93 beat Okta's score of 0.89 indicating that Cellebrite DI is being referred to more favorably in the news media.
Summary
Cellebrite DI beats Okta on 10 of the 18 factors compared between the two stocks.
Get Cellebrite DI News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLBT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellebrite DI Competitors List
Related Companies and Tools
This page (NASDAQ:CLBT) was last updated on 3/3/2025 by MarketBeat.com Staff
Free CLBT Stock Alerts